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Associations between atrial fibrillation (AF), outcomes, and response to antiplatelet therapies in patients
with acute coronary syndrome (ACS) managed medically without revascularization remain uncertain. We
examined these associations for medically managed ACS patients randomized to dual antiplatelet therapy
(DAPT) using patient data from the TRILOGY ACS trial. DAPT included aspirin plus clopidogrel 75 mg/d or
prasugrel 10 mg/d (5 mg/d for those <60 kg or age ≥75 years). Patients receiving oral anticoagulants were
excluded. Cox proportional hazards regression modeling was used to characterize associations between
patients with AF (AF+) vs those without (AF−) and risk of ischemic and bleeding events, and to explore effects
of randomized treatment on outcomes. Among 9101 patients with baseline AF status, 710 (7.8%) had AF. AF+
patients were older and had more comorbidities. Unadjusted associations of the composite of cardiovascular
death/myocardial infarction/stroke were significantly higher among AF patients at 30 months (31.1% vs 18.4%;
HR: 1.61, 95% CI: 1.35-1.92, P < 0.001), but differences did not persist after adjustment (HR: 1.16, 95% CI:
0.97-1.39, P = 0.11). When individual components of the composite endpoint were evaluated, 30-month risk of
events in AF+ patients was significantly higher. Thirty-month risk of all-cause death was significantly higher
in AF+ patients: 18.1% vs 11.1% (HR: 1.62, 95% CI: 1.30-2.02, P < 0.001). There was no significant interaction
with randomized treatment and AF for the primary endpoint. Among medically managed high-risk ACS patients
receiving DAPT, AF was associated with higher unadjusted risks of ischemic and bleeding outcomes that were
similar by treatment group.
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Introduction
Atrial fibrillation (AF) is the most common sustained
cardiac arrhythmia and is a risk factor for ischemic stroke
and cardiovascular mortality.1 In patients with stable
coronary artery disease, the prevalence of AF is 12.5%2–4
and is associated with a higher risk of cardiovascular
outcomes.5 Dual antiplatelet therapy (DAPT), comprising
aspirin and a P2Y12 receptor inhibitor, is standard of care
following percutaneous coronary intervention (PCI) for
patients with acute coronary syndromes (ACS). However, a
substantial proportion of these patients have AF, for which
oral anticoagulants (OACs) provide superior prevention
of stroke compared with antiplatelet agents; but, when
combined with DAPT, they may significantly increase the
risk of bleeding, specifically when prescribed with a newer
P2Y12 receptor inhibitor such as prasugrel or ticagrelor.6–11
Patients with both AF and ACS present a clinical conun-
drum, given uncertainty regarding the optimal antithrom-
botic strategy, as well as for those undergoing PCI (A
Study Exploring Two Strategies of Rivaroxaban and One
of Oral Vitamin K Antagonist in Patients With Atrial
Fibrillation Who Undergo Percutaneous Coronary Inter-
vention [PIONEER AF-PCI; http://www.ClinicalTrials.gov
NCT01830543] and Evaluation of Dual Therapy With Dabi-
gatran vs Triple Therapy With Warfarin in Patients With
AF That Undergo a PCI With Stenting [REDUAL-PCI;
NCT02164864]). Currently, controversy exists regarding
the prognostic role of AF in patients with ACS,12,13
and to date there are no studies analyzing the associa-
tion between AF and outcomes among ACS patients at
highest risk—specifically, elderly patients managed med-
ically without coronary revascularization. The randomized
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Targeted Platelet Inhibition to Clarify the Optimal Strategy
to Medically Manage Acute Coronary Syndromes (TRIL-
OGY ACS; NCT00699998) trial included a prospective
analysis plan to evaluate the prognostic role of AF in elderly
patients with ACS. Accordingly, using the TRILOGY ACS
study, we sought to (1) determine the risk of ischemic and
bleeding outcomes in high-risk patients with both AF and
ACS who were medically managed with DAPT and without
planned invasive revascularization; (2) evaluate the safety
and efficacy of DAPT with prasugrel or clopidogrel among
high-risk elderly patients with AF and ACS; and (3) evaluate
the magnitude of platelet aggregation in AF patients with
recent ACS using platelet reactivity units (PRUs) obtained
from the substudy of the TRILOGY ACS trial.
Methods
Trial Design
The design, methods, and primary results of TRILOGY ACS
have been previously described.14,15 Briefly, TRILOGY ACS
was an international, randomized, active-controlled, double-
blinded, double-dummy trial that enrolled 9326 intention-
to-treat (ITT) patients who were planned to undergo
medical management without invasive revascularization
for unstable angina (UA) or non–ST-segment elevation
myocardial infarction (NSTEMI). Study participants were
randomly assigned in a 1:1 fashion to receive prasugrel
10 mg/d (5 mg/d in patients <60 kg body weight or age
≥75 years) or clopidogrel (75 mg/d), plus background low-
dose aspirin therapy.15 Participants for whom AF status at
baseline was missing (n = 225, 2.4%) were excluded from
the present analysis. A final cohort of 9101 participants
was assessed for ischemic outcomes; for the analysis of
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safety outcomes, patients were assessed during the ‘‘at-
risk’’ interval of actual study-drug treatment through 7 days
after study-drug discontinuation (n = 9022).
All appropriate national regulatory agencies and institu-
tional review boards at each participating center approved
the TRILOGY ACS study and all participants gave informed
consent. An international multidisciplinary executive com-
mittee designed the study and takes responsibility for the
accuracy and completeness of all data and subsequent
analyses.
Clinical Outcomes
The primary efficacy endpoint was the composite of
cardiovascular death, nonfatal myocardial infarction (MI), or
nonfatal stroke. An independent cardiovascular adjudication
committee whose members were blinded to study-group
assignments evaluated suspected ischemic and bleeding
endpoints. Key bleeding and safety endpoints included
Global Use of Strategies to Open Occluded Coronary
Arteries (GUSTO) criteria for severe or life-threatening
bleeding unrelated to coronary artery bypass grafting
and Thrombolysis in Myocardial Infarction (TIMI) criteria
for major bleeding unrelated to coronary artery bypass
grafting.16,17
Platelet Function Substudy
A total of 2564 TRILOGY ACS subjects from participating
sites were enrolled in a prospective platelet function
substudy that evaluated differences in platelet reactivity
over time for patients receiving prasugrel vs clopidogrel.18
Briefly, substudy participants underwent serial platelet
reactivity assessments (as measured in P2Y12 PRUs) with
the VerifyNow system (Accriva Diagnostics, San Diego,
CA). The PRU measurements were performed at baseline,
at 2 hours, and at 1, 3, 6, 12, 18, 24, and 30 months
following randomization. Participants receiving prasugrel
10 mg/d exhibited significantly lower platelet reactivity vs
those receiving clopidogrel, but no significant independent
associations with ischemic endpoints were seen after
adjustment.18
Atrial Fibrillation
Patients included in this secondary analysis had a history of
AF prior to or during the index hospitalization and were not
taking an OAC. In addition to identifying a history of prior
or current AF, additional characteristics were collected,
including duration of AF, a history of prior thromboembolic
events associated with AF prior to randomization, the use
of OACs prior to randomization, antiarrhythmic drug use
within the previous 12 months prior to randomization, and
discontinuation of OAC due to a bleeding complication. Site
investigators were not queried as to the overall use of OAC
in patients with AF and why patients were not treated with
OAC prior to an ACS event.
Statistical Analysis
Baseline characteristics have been summarized according
to AF status at baseline. This analysis analyzed patients with
history of current or prior AF (AF+) vs those without history
of AF (AF−). Continuous variables are presented as median
(interquartile range [IQR]), and differences are compared
using the Wilcoxon rank-sum test. Categorical variables
are presented as counts (percentages), and differences are
compared using the Pearson χ2 test when cell frequencies
are sufficient; otherwise, an exact test is used.
For patients with a history of AF (current or prior), the
duration of AF (in months), stoppage of an OAC due to a
bleeding event, and treatments received within the last 12
months are summarized according to treatment and for the
entire ITT population. For continuous variables, descriptive
statistics (ie, mean, SD, median, minimum, and maximum)
are reported, and differences between treatments are
compared using the Wilcoxon rank-sum test. Categorical
variables are presented as counts (percentages), and
differences are compared using the Pearson χ2 test if cell
frequencies are sufficient; otherwise, an exact test is used.
For each ischemic and bleeding endpoint, the total
number of events and Kaplan-Meier event rate estimate
(95% confidence interval [CI]) through 30 months after
randomization are shown separately for AF+ vs AF−
patients. Events across the follow-up period are compared
by AF status using the log-rank test. To examine the
relationship between AF and clinical outcomes, unadjusted
and adjusted Cox proportional hazards regression models
were developed that tested the univariate and multivariate
association of AF (AF+ vs AF−) and each clinical outcome.
The TRILOGY ACS adjustment models have been built
for each ischemic and bleeding outcome and control for
baseline characteristics and risk factors.19 When fitting the
adjustment model, the proportional hazards assumption was
checked for each variable and the linearity assumption was
checked for each continuous variable. If the proportional
hazard assumption was violated, an interaction of the vari-
able with log-transformed time was included in the model.
If the linearity assumption was violated, a restricted cubic
spline was used to approximate the nonlinear relationship
of the variable with the outcome. For a full description of the
TRILOGY ACS adjustment models used in this analysis, see
Supporting Information in the online version of this article.
Only patients enrolled in the platelet function sub-
study (n = 2564) were considered for the analysis com-
paring platelet function of medically managed ACS patients
with/without a history of AF and treated with prasugrel or
clopidogrel. For each treatment group, the Wilcoxon rank-
sum test was used to test whether the distribution of 30-day
PRU was different between patients with vs without AF.
Results are presented as medians (IQR). To test for a differ-
ence across the 4 groups, the Kruskal-Wallis test was used.
All statistical tests are 2-sided, and a P value <0.05
was considered statistically significant. All analyses were
performed using SAS version 9.2 (SAS Institute Inc., Cary,
NC) and R version 3.0.3 (R Foundation, Vienna, Austria)
by independent statisticians at the Duke Clinical Research
Institute in Durham, North Carolina.
Results
A total of 9326 TRILOGY ACS participants underwent
randomization according to the ITT definition. As previously
noted, 225 (2.4%) participants who lacked data regarding
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Table 1. Baseline Characteristics of the Study Population
History of Prior or Current AF
Characteristic Yes, n = 710a No, n = 8391b P Value
Demographics
Sex <0.001
F 323 (45.5) 3237 (38.6)
M 387 (54.5) 5154 (61.4)
Median age, y 72.0 (66.0–78.0) 65.0 (58.0–73.0) <0.001
Age ≥75 y 282 (39.7) 1718 (20.5) <0.001
Median weight, kg 77.0 (66.1–88.0) 75.0 (65.0–86.0) 0.008
Weight <60 kg 87/709 (12.3) 1287/8385 (15.3) 0.028
Region <0.001
Central/Eastern Europe 341 (48.0) 2681 (32.0)
East Asia 57 (8.0) 684 (8.2)
Indian subcontinent 17 (2.4) 1114 (13.3)
Latin America 68 (9.6) 1190 (14.2)
Mediterranean basin 33 (4.6) 594 (7.1)
North America 104 (14.6) 1129 (13.5)
Western Europe/Scandinavia 77 (10.8) 876 (10.4)
Rest of world 13 (1.8) 123 (1.5)
Randomized treatment 0.538
Prasugrel 347 (48.9) 4202 (50.1)
Clopidogrel 363 (51.1) 4189 (49.9)
Prasugrel dose <0.001
5 mg 153/347 (44.1) 1317/4202 (31.3)
10 mg 194/347 (55.9) 2885/4202 (68.7)
Presentation characteristics
Median time from presentation until start of study drug, h 117.3 (71.8–167.4) 107.3 (61.5–158.9) <0.001
Killip class II–IV on presentation 137/709 (19.3) 965/8387 (11.5) <0.001
Disease classification 0.881
UA/unknown 217 (30.6) 2542 (30.3)
NSTEMI 493 (69.4) 5849 (69.7)
Cardiovascular risk factors
Family history of CAD 186/595 (31.3) 2269/7544 (30.1) 0.545
HTN 636 (89.6) 6802/8370 (81.3) <0.001
Hyperlipidemia 428/671 (63.8) 4672/7993 (58.5) 0.007
DM 228 (32.1) 3217/8374 (38.4) <0.001
Current/recent smokingc 94/703 (13.4) 1718/8312 (20.7) <0.001
CVD history
Prior MI 292/706 (41.4) 3582/8333 (43.0) 0.402
Prior PCI 194/707 (27.4) 2167/8351 (25.9) 0.386
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Table 1. Continued
History of Prior or Current AF
Characteristic Yes, n = 710a No, n = 8391b P Value
Prior CABG 134 (18.9) 1265/8373 (15.1) 0.008
Prior PAD 67/690 (9.7) 592/8270 (7.2) 0.014
Prior HF 238/707 (33.7) 1348/8350 (16.1) <0.001
Baseline risk assessment
Median GRACE risk score 138.0 (120.0–155.0) 120.0 (104.0–138.0) <0.001
CHA2DS2-VASc risk of stroke
Mean score 3.7 ± 1.4 2.9 ± 1.4 <0.001
Score <0.001
1 30 (4.2) 1022 (12.2)
2 91 (12.8) 2155 (25.7)
3 196 (27.6) 2287 (27.3)
4 200 (28.2) 1623 (19.3)
5 122 (17.2) 784 (9.3)
6 49 (6.9) 248 (3.0)
7 14 (2.0) 62 (0.7)
8 3 (0.4) 4 (0.0)
9 1 (0.1) 2 (0.0)
Baseline laboratory values
Median SBP, mm Hg 130.0 (120.0–140.0) 129.0 (119.0–139.0) 0.054
Median heart rate, bpm 68.0 (61.0–76.0) 69.0 (62.0–76.0) 0.412
Median Hgb, g/dL 13.4 (12.4–14.5) 13.6 (12.4–14.7) 0.108
Median CrCl, mL/min 64.4 (46.5–84.2) 73.8 (55.1–97.0) <0.001
Prerandomization procedures
Angiography performed 263 (37.0) 3464 (41.3) 0.027
Concomitant medications at randomization
ASA
Daily dose <100 mg 246 (34.6) 2808 (33.5) 0.521
Daily dose 100–250 mg 369 (52.0) 4460 (53.2) 0.545
Daily dose >250 mg 54 (7.6) 583 (6.9) 0.510
β-Blocker 551 (77.6) 6530 (77.8) 0.894
ACEI/ARB 577 (81.3) 6284 (74.9) <0.001
Statin 563 (79.3) 7033 (83.8) 0.002
PPI 185 (26.1) 2099 (25.0) 0.539
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; ASA, acetylsalicylic acid (aspirin);
CABG, coronary artery bypass grafting; CAD, coronary artery disease; CHA2DS2-VASc, congestive heart failure, HTN, age ≥75 y, DM, stroke/TIA, vascular
disease, age 65–74 y, sex category (women); CrCl, creatinine clearance; CVD, cardiovascular disease; DM, diabetes mellitus; F, female; GRACE, Global
Registry of Acute Coronary Events; HF, heart failure; Hgb, hemoglobin; HTN, hypertension; IQR, interquartile range; M, male; MI, myocardial infarction;
NSTEMI, non–ST-segment elevation myocardial infarction; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; PPI, proton pump
inhibitor; SBP, systolic blood pressure; SD, standard deviation; TIA, transient ischemic attack; UA, unstable angina.
Data are presented as n (%), mean ± SD, or median (IQR).
aTotal no. of patients is 710 unless otherwise noted. b Total no. of patients is 8391 unless otherwise noted. c Smoking within 30 days of randomization.
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baseline AF status were excluded from this analysis. Key
clinical characteristics of AF+ patients are shown in Table 1.
In this medically managed population, AF+ patients were
older and more likely to have an increased number of
medical comorbidities, as well as higher CHA2DS2-VASc
scores (congestive heart failure, hypertension, age ≥75 y,
diabetes mellitus, stroke/transient ischemic attack, vascular
disease, age 65–74 y, sex category [women]) and higher
Global Registry of Acute Coronary Events (GRACE) risk
scores.
Within the ITT population, 4549 (50.0%) participants were
randomly assigned to receive prasugrel and 4552 (50.0%)
were randomly assigned to clopidogrel. The proportion of
AF+ within the ITT population (n = 710, 7.8%) was balanced
between treatment groups (7.6% vs 8.0%; P = 0.54). The
median duration of AF for both treatment groups was 1
month (P = 0.81), with 64.5% (453/702) of AF+ patients
reporting duration of AF ≤1 month. There was no significant
difference between treatment groups in the proportion
of AF+ patients who were treated with antiarrhythmic
drug therapy in the previous 12 months (38.0% vs 37.7%;
P = 0.97). Groups were balanced with respect to previous
treatment with OACs (19.9% vs 22.3%; P = 0.72). There
was no difference in previous thromboembolic events
associated with AF between treatment groups (2.0% vs 2.2%;
P = 0.41).
Ischemic Outcomes
The unadjusted association of the primary composite
endpoint of cardiovascular death, MI, or stroke occurred
with increased risk in AF+ patients at 30 months: 31.1% vs
18.4% (hazard ratio [HR]: 1.61, 95% CI: 1.35-1.92, P < 0.001;
Table 2/Figure 1). When all secondary outcomes were
evaluated, there was a significantly increased risk of
events, particularly stroke, in AF+ patients at 30 months,
although the overall incidence of stroke was low (Table 2,
Figure 2). The rate of all-cause death was significantly
higher in AF+ patients at 30 months: 18.1% vs 11.1% (HR:
1.62, 95% CI: 1.30-2.02, P < 0.001). After adjustment, there
was no difference in rates of the composite endpoint of
cardiovascular death, MI, or stroke (HR: 1.16, 95% CI: 0.97-
1.39, P = 0.11). Rates of all-cause death were also similar
between AF+ and AF− patients (HR: 1.10, 95% CI: 0.87-1.39,
P = 0.42).
Although no significant treatment interactions were found
for either the primary composite endpoint or secondary
component endpoints, a significant interaction was observed
for AF+ patients treated with prasugrel and an increased
risk of MI (P for interaction = 0.01).
Bleeding Outcomes
Rates of major bleeding (GUSTO severe or life-threatening
bleeding; GUSTO severe, life-threatening, or moderate
bleeding; TIMI major bleeding) at 30 months were similar
between both AF groups. The TIMI major or minor bleeding
was higher in patients with AF: 8.3% vs 3.0% (HR: 1.76, 95%
CI: 1.10-2.81, P = 0.016; Table 2). This effect, however, was
attenuated after adjustment (HR: 1.46, 95% CI: 0.90-2.36,
P = 0.124). There was no significant interaction for AF by
treatment for any bleeding endpoint.
Study-Drug Discontinuation
Rates of study-drug discontinuation were highest among
AF+ patients. The primary indications for study-drug
discontinuation among AF+ patients include patient
decision and adverse events (Table 3). Among AF+ patients,
the rate of study-drug discontinuation for the initiation of
OAC therapy was low but significantly higher than in non-AF
patients. In addition, there were no significant differences in
loss to follow-up for either AF+ or AF− study participants
(0.3% vs 0.2%; P = 0.34).
Atrial Fibrillation and Platelet Function
Among patients randomized to clopidogrel, there was no
statistically significant difference in the median PRU values
between AF+ patients (212 PRU [IQR, 140–246]) and AF−
patients (206 PRU [IQR, 143–263]; P = 0.63). However,
among those randomized to prasugrel, AF+ patients had
significantly higher median PRU values (131 PRU [IQR,
76–197]) than AF− patients (85 PRU [IQR, 42–154]);
P < 0.001). In addition, AF+ patients receiving prasugrel
had lower median PRU values than did those receiving
clopidogrel.
Discussion
This study, which examined the association of AF with
ischemic and bleeding outcomes in ACS patients treated
medically with DAPT but without oral anticoagulation, yields
several important findings. First, AF is accompanied by
older age, an increased burden of comorbidities, as well as
an increased risk of stroke/systemic embolism and death
or death/MI, as evidenced by higher CHA2DS2-VASc and
GRACE risk scores, respectively. Second, the presence
of AF is associated with significantly higher median PRU
measurement values at 30 days among AF patients treated
with the 5-mg dose of prasugrel and with an increased
risk of MI in this subgroup. Third, the presence of AF in
study participants with UA/NSTEMI who were treated with
DAPT was not associated with worse ischemic or bleeding
outcomes after adjustment when compared with patients
without AF.
Atrial fibrillation has been assumed to be a causal
factor associated with increased morbidity and mortality
in patients with MI. Potential mechanistic explanations
include loss of atrial contraction, decreased atrioventricular
synchrony, elevated filling pressures with enhanced remod-
eling and worsening left ventricular systolic dysfunction, and
increased rates of ventricular arrhythmias and sudden car-
diac death.20–22 Previous studies have shown an increased
risk of major adverse cardiovascular events and all-cause
mortality in AF patients with ACS.23–29 However, contro-
versy still exists as to whether AF plays a prognostic role in
poor outcomes or is merely a marker of worsening risk due
to an increased number of confounding comorbidities.
In our analysis from a large, randomized trial of medically
managed patients with UA/NSTEMI, we demonstrated that
patients with AF do not have an increased risk of ischemic
or bleeding outcomes after covariate adjustment. This
suggests that patients with AF and ACS within the TRILOGY
ACS cohort who undergo medical management without
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Table 2. Association of AF on the Risk of Ischemic and Bleeding Outcomes







Cardiovascular death, MI, or stroke 1.61 (1.35-1.92) 1.16 (0.97-1.39) 0.067
No. of events 138 1085
Event rate at 30 months (95% CI) 31.1 (25.1-37.2) 18.4 (17.1-19.6)
Cardiovascular death 1.69 (1.32-2.16) 1.15 (0.89-1.49) 0.549
No. of events 73 537
Event rate at 30 months (95% CI) 16.7 (11.6-21.7) 9.3 (8.4-10.2)
MI 1.48 (1.16-1.88) 1.09 (0.85-1.40) 0.013
No. of events 75 640
Event rate at 30 months (95% CI) 16.3 (12.3-20.3) 11.1 (10.0-12.2)
Stroke 2.23 (1.37-3.63) 1.59 (0.96-2.65) 0.401
No. of events 19 107
Event rate at 30 months (95% CI) 6.6 (2.2-11.0) 2.0 (1.5-2.4)
All-cause death 1.62 (1.30-2.02) 1.10 (0.87-1.39) 0.373
No. of events 88 672
Event rate at 30 months (95% CI) 18.1 (13.5-22.7) 11.1 (10.2-12.1)
GUSTO severe/life-threatening bleeding 1.89 (0.80-4.45) 1.40 (0.58-3.37) 0.685
No. of events 6 42
Event rate at 30 months (95% CI) 3.4 (0.0-7.3) 0.9 (0.6-1.2)
GUSTO severe/life-threatening/moderate bleeding 1.33 (0.77-2.30) 1.01 (0.58-1.78) 0.310
No. of events 14 139
Event rate at 30 months (95% CI) 6.8 (2.0-11.7) 2.8 (2.3-3.3)
TIMI major bleeding 0.96 (0.44-2.06) 0.76 (0.35-1.65) 0.716
No. of events 7 97
Event rate at 30 months (95% CI) 3.9 (0.0-7.9) 2.0 (1.5-2.4)
TIMI major or minor bleeding 1.76 (1.10-2.81) 1.46 (0.90-2.36) 0.189
No. of events 20 150
Event rate at 30 months (95% CI) 8.3 (3.4-13.2) 3.0 (2.5-3.6)
Abbreviations: AF, atrial fibrillation; CI, confidence interval; GUSTO, Global Use of Strategies to Open Occluded Coronary Arteries; HR, hazard ratio; MI,
myocardial infarction; TIMI, Thrombolysis In Myocardial Infarction.
aSafety outcomes computed on the population of patients who received study treatment (AF+: n = 702; AF−: n = 8320). bAF-by-treatment interaction P
values are from the adjusted models.
oral anticoagulation or planned invasive revascularization
represent a high-risk, older population with a greater burden
of confounding comorbid conditions that accompany AF.
To date, few randomized studies have examined outcomes
from patients with AF and ACS by treatment strategy.
Ruiz-Nodar and colleagues have described the largest
randomized cohort of patients with AF and ACS undergoing
revascularization with PCI and subsequent outcomes based
on antithrombotic therapy.30 In this 2-center cohort of
patients with AF and ACS who were treated with medical
therapy and revascularization, those discharged on DAPT
comprising aspirin and clopidogrel (n = 174, 40.8%) had
increased mortality compared with patients receiving triple
oral antithrombotic therapy (n = 213, 50%): 38.7% vs 26.5%
(HR: 4.9, 95% CI: 1.61-7.54, P = 0.002), as well as higher
rates of major adverse cardiovascular events: 27.8% vs 17.8%
(HR: 3.43, 95% CI: 2.17-11.1, P < 0.01), but no differences in
major or minor bleeding.30
In comparison, observational studies have demonstrated
conflicting results with regard to outcomes for patients
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Figure 1. Kaplan-Meier estimates of the composite of cardiovascular death, MI, or stroke through 30 months in patients with AF (black line) and without AF
(blue line). Abbreviations: AF, atrial fibrillation; MI, myocardial infarction.
Figure 2. Kaplan-Meier estimates of GUSTO severe/life-threatening/moderate bleeding through 30 months in patients with AF (black line) and without AF
(blue line). Abbreviations: AF, atrial fibrillation; GUSTO, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries.
with AF and ACS based on antithrombotic drug regimens.
Hansen et al showed that combination therapy with OACs
and DAPT is associated with a significantly higher risk of
bleeding compared with monotherapy.9 Conversely, Goa
et al showed that combination therapy with warfarin and
DAPT did not decrease the rates of MI or mortality but did
increase major bleeding.31
Our analysis cohort is derived from a randomized
population of elderly participants, who are at greater risk for
developing AF. In addition, patients were balanced with
respect to study-drug treatment with a P2Y12 receptor
inhibitor (prasugrel: n = 347, 48.9%; clopidogrel: n = 363,
51.1%) and were not treated with OACs. In this study, we
observed significant increases in the incidence of primary-
endpoint events in participants with both ACS and AF.
However, after adjusting for possible confounders such as
age, sex, hypertension, history of diabetes mellitus, systolic
blood pressure, heart rate, Killip class at presentation, and
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Table 3. Primary Reason for Permanent Study-Drug Discontinuation
Disposition, n (%) All Patients, N = 9022 AF+, n = 702 AF−, n = 8320 P Valuea
Permanent study-drug discontinuation 2076 (23.0) 221 (31.5) 1855 (22.3) <0.001
Subject had a procedure 21 (0.2) 1 (0.1) 20 (0.2) 1.00
Adverse event 793 (8.8) 91 (13.0) 702 (8.4) <0.001
Hemorrhagic 261 (2.9) 24 (3.4) 237 (2.8) 0.39
Nonhemorrhagic 532 (5.9) 67 (9.5) 465 (5.6) <0.001
Need for OAC 102 (1.1) 25 (3.6) 77 (0.9) <0.001
Investigator decision 97 (1.1) 7 (1.0) 90 (1.1) 0.84
Subject decision 981 (10.9) 88 (12.5) 893 (10.7) 0.14
Study drug unblinded 3 (0.0) 0 (0.0) 3 (0.0) 1.00
Entry criteria not met 62 (0.7) 7 (1.0) 55 (0.7) 0.33
Lost to follow-up 16 (0.2) 2 (0.3) 14 (0.2) 0.34
Abbreviations: AF, atrial fibrillation; OAC, oral anticoagulation.
aP value based on Fisher exact test.
history of MI, the rates of primary-endpoint events were
not significantly different between study participants with
vs without AF. These findings suggest that comorbidities
and not AF play an increased prognostic role in
outcomes for ACS patients treated primarily with medical
therapy, and that AF is merely one marker of overall
increased risk.
Although OAC has been proven to be superior to
DAPT in reducing stroke, DAPT offers a reasonable
option for reducing ischemic outcomes including both all-
cause and cardiac mortality. In our analysis, DAPT was
chosen by treating physicians and was not an exclusion
criterion in the trial. The results from our analysis are
important given the documented suboptimal utilization of
oral anticoagulation in patients with AF.32,33 Dual antiplatelet
therapy has been demonstrated to reduce the risk of
ischemic endpoints including stroke and systemic embolism
(the Atrial Fibrillation Clopidogrel Trial With Irbesartan
for Prevention of Vascular Events [ACTIVE W] trial,
NCT00243178).34 Additionally, long-term use of DAPT with
a P2Y12 receptor inhibitor has been shown to reduce the
risk ischemic endpoints including stroke (Prevention of
Cardiovascular Events in Patients With Prior Heart Attack
Using Ticagrelor Compared to Placebo on a Background of
Aspirin [PEGASUS-TIMI 54], NCT01225562).35
Atrial fibrillation is known to cause increased platelet
activation. However, the effect of specific P2Y12 receptor
inhibitors on PRU values in the setting of AF is unknown.
In our study, the 5-mg/d dose of prasugrel was used more
frequently among elderly AF+ patients to decrease the risk
of bleeding, which explains the difference in observed PRU
values among patients taking prasugrel. In addition, among
AF+ patients, the PRU value associated with prasugrel
is lower than the PRU value associated with clopidogrel.
This suggests that prasugrel did reduce platelet reactivity
to a greater extent than clopidogrel for patients with
and without AF. However, in patients with AF+ vs AF−
on prasugrel, median PRU values were higher for those
AF+ patients receiving prasugrel, suggesting that full
suppression of platelets was not achieved. It is unclear from
this study whether multiple factors including prasugrel
dosing, comorbidities, higher percentage of elderly patients
in the AF+ group, or AF type led to such a finding and
whether the inability to fully suppress platelet aggregation
for AF+ patients on prasugrel led to increased risk of MI in
the prasugrel group.
Study Limitations
Our study has several limitations. First, the present
investigation is a post hoc analysis of prospectively collected
clinical trial data, and the findings are only hypothesis-
generating. Second, AF+ patients were defined as those with
either current or prior AF as a clinical variable only, without
detailed information or a confirmatory electrocardiogram
regarding timing or type of AF or proof of AF, respectively.
Third, patients receiving OAC therapy were excluded from
this study, and the reasons for not using an OAC were
not collected on the baseline case-report form. In addition,
patients were only initiated on OAC therapy after study-
drug discontinuation. Finally, there may be unmeasured
confounders associated with AF that potentially could have
influenced comparisons.
Conclusion
Among a randomized population of high-risk elderly patients
with ACS managed medically with DAPT and without OAC
therapy or invasive revascularization, current or prior AF
was not associated with higher adjusted risks of ischemic
and bleeding outcomes. Further studies are needed to
elucidate both the contribution of AF to the constellation
of comorbid conditions affecting prognosis in this patient
population as well as optimal therapeutic strategies for
patients with both ACS and AF.
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